Proteocyte Diagnostics

Proteocyte Diagnostics has developed Straticyte, a clinically available laboratory test that uses proprietary algorithms and protein biomarker analysis to predict the five-year risk of progression from oral precancerous lesions to invasive oral cancer. The technology enables clinicians to stratify patients by risk level, supporting more personalized treatment decisions. Early detection through this approach can improve survival rates and reduce unnecessary interventions for low-risk patients. The company’s solution integrates seamlessly into existing biopsy workflows without requiring additional tissue samples. Clinical results indicate improved accuracy in identifying high-risk lesions compared to standard histopathology alone.